Oncolytic virus therapy for malignant gliomas: entering the new era.

Published in: Expert opinion on biological therapy (2023)

For the next decade, clinical trials and preclinical and translational research will continue to drive the development of innovative OV treatments for malignant gliomas and benefit patients and define new OV biomarkers.

Keyphrases

clinical trial
high grade
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
stem cells
bone marrow
phase ii
open label
phase iii